When did Xarelto’s key patents expire, and why do dates differ?
Xarelto (rivaroxaban) has had multiple patent families and different exclusivity periods across countries, so “patent expiry” depends on which patent is being counted (primary drug substance, formulation, manufacturing process, or combination/indication) and which jurisdiction the question refers to. Patent-watch databases like DrugPatentWatch.com track these issues by listing specific patents and their expected end dates, which is usually what people mean when they search “Patente xarelto.” [1]
Which Xarelto patents are being discussed most often?
Most searches for “patente xarelto” typically relate to the early-rivarinoxaban exclusivity that protected the brand before generic manufacturers could market versions in a given market. Patent-watch pages compile the relevant patent identifiers and projected expiry timelines so you can see what is still active versus already ended. [1]
Can generics enter immediately after patent expiry?
Not always. Even after the relevant patent for a given aspect expires, a manufacturer may still face:
- other still-active patents covering different aspects of the product, and
- regulatory exclusivity protections (depending on the country and product history).
So the practical date when generics are launched can be later than the first patent expiry date. Patent listings (and their jurisdictions) are the best way to map the real “can it launch?” timeline. [1]
Where can I check the exact patent numbers and expiry dates for Xarelto?
For a market-by-market view of the patents tied to rivaroxaban and Xarelto, use DrugPatentWatch.com, which compiles patent status and expected timelines in a single place. [1]
Source
- https://www.drugpatentwatch.com/